BTIG analyst David Larsen lowered the firm’s price target on LifeMD to $7 from $8 but keeps a Buy rating on the shares after its Q4 results. The analyst is positive on the company having reduced costs and gotten to EBITDA breakeven, along with the profitability of the software business, even though the reduced marketing spend has caused some slow-down in revenue growth. The firm also believes that LifeMD guidance for 2023 seems reasonable.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LFMD:
- LifeMD, Inc. Reports Fourth Quarter/ Full Year 2022 Results; Achieves Consolidated Adjusted EBITDA Profitability
- LifeMD announces closing of $40M credit facility
- LifeMD, Inc. to Announce Fourth Quarter, Full Year 2022 Financial Results on March 22, 2023
- LifeMD Appoints Dr. Joan LaRovere to its Board of Directors
- LifeMD appoints LaRovere to board of directors
